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Although an association between excessive alcohol consumption and psoriasis has been identified, 
such a link is not established in other chronic inflammatory skin conditions. We examined the 
prevalence of alcohol use disorders (AUD) using the validated Alcohol Use Disorders Identification 
Test (AUDIT) in patients with different skin diseases. In this observational questionnaire single centre 
study, 609 patients were recruited in four inflammatory groups (psoriasis, eczema, lupus and other) 
and a reference group with non-inflammatory skin conditions. We used three validated screening 
tools: the alcohol use disorders identification test (AUDIT), hospital anxiety and depression score 
(HADS) and dermatology life quality index (DLQI). An AUDIT score of 8 defined an alcohol use 
disorder. 22.7% of our population had AUD. AUD were more prevalent in males and those with later 
date of birth. Patients with inflammatory skin conditions had a higher prevalence of AUD than the 
reference group, 24.5% vs. 14.3% respectively. In the primary analysis, the odds ratio (OR), (with 
95% CI) for AUD among psoriasis patients relative to the control group was 2.69 (1.49–4.69) and 
adjusting for gender and age 1.65 (0.86–3.17). Exploratory analyses showed the OR for AUD in 
eczema patients relative to the reference group was 3.00 (1.69–5.33) and adjusting for gender and 
age 2.00 (1.03–3.85). The mean DLQI score was 10.29 (SD 7.57) in the eczema group and 7.71 (SD 
6.73) in the psoriasis group. Our data support the previously known problem of AUD in patients with 
psoriasis using a validated measure, the AUDIT. For the first time we have shown that AUD are more 
prevalent in eczema patients comparing to a reference population. Despite controlling for age and 
gender the possibility of other confounders cannot be entirely excluded and further investigation is 
needed in larger populations in non-hospital settings to confirm these findings. 
 
